000144954 001__ 144954
000144954 005__ 20240920135617.0
000144954 0247_ $$2doi$$a10.3390/biomedicines12081763
000144954 0248_ $$2sideral$$a139737
000144954 037__ $$aART-2024-139737
000144954 041__ $$aeng
000144954 100__ $$0(orcid)0000-0002-3830-7847$$aAtrián-Blasco, Elena
000144954 245__ $$aHeteronuclear Complexes with Promising Anticancer Activity against Colon Cancer
000144954 260__ $$c2024
000144954 5060_ $$aAccess copy available to the general public$$fUnrestricted
000144954 5203_ $$aThis study investigates the activity of novel gold(I) and copper(I)/zinc(II) heteronuclear complexes against colon cancer. The synthesised heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes were characterised and evaluated for their anticancer activity using human colon cancer cell lines (Caco-2). The complexes exhibited potent cytotoxicity, with IC50 values in the low micromolar range, and effectively induced apoptosis in cancer cells. In the case of complex [Cu{Au(Spy)(PTA)}2]PF6 (2), its cytotoxicity is ×10 higher than its mononuclear precursor, while showing low cytotoxicity towards differentiated healthy cells. Mechanistic studies revealed that complex 2 inhibits the activity of thioredoxin reductase, a key enzyme involved in redox regulation, leading to an increase in reactive oxygen species (ROS) levels and oxidative stress, in addition to an alteration in DNA’s tertiary structure. Furthermore, the complexes demonstrated a strong binding affinity to bovine serum albumin (BSA), suggesting the potential for effective drug delivery and bioavailability. Collectively, these findings highlight the potential of the investigated heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes as promising anticancer agents, particularly against colon cancer, through their ability to disrupt redox homeostasis and induce oxidative stress-mediated cell death.
000144954 536__ $$9info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/DGA/B16-23R$$9info:eu-repo/grantAgreement/ES/DGA/E07-23R$$9info:eu-repo/grantAgreement/ES/MICINN AEI/PID2019-104915RB-I00$$9info:eu-repo/grantAgreement/ES/MICINN AEI/PID2022-13686INB-I00$$9info:eu-repo/grantAgreement/EUR/SUDOE/INTERREG/NEWPOWER-S1-1.1-E01116
000144954 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000144954 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000144954 700__ $$aSáez, Javier
000144954 700__ $$0(orcid)0000-0002-3595-7668$$aRodriguez-Yoldi, Maria Jesús$$uUniversidad de Zaragoza
000144954 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, Elena$$uUniversidad de Zaragoza
000144954 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000144954 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000144954 773__ $$g12, 8 (2024), 1763 [20 pp.]$$tBiomedicines$$x2227-9059
000144954 8564_ $$s4258122$$uhttps://zaguan.unizar.es/record/144954/files/texto_completo.pdf$$yVersión publicada
000144954 8564_ $$s2768209$$uhttps://zaguan.unizar.es/record/144954/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000144954 909CO $$ooai:zaguan.unizar.es:144954$$particulos$$pdriver
000144954 951__ $$a2024-09-20-13:01:17
000144954 980__ $$aARTICLE